Novartis downplays late-stage asthma drug failures

Novartis' experimental asthma treatment fevipiprant failed to improve lung function in a pair of Phase 3 studies of patients with moderate asthma, the Swiss pharma disclosed Tuesday in its third quarter earnings report.